Quantum BioPharma's MS Imaging Study Reaches Halfway Point with Encouraging Preliminary Data

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the midpoint in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study show encouraging signals in acute MS lesions, which could lead to a more precise method for measuring myelin loss and repair.

The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, a distinction that is critical for assessing disease progression and treatment efficacy. The study’s progress is directly relevant to Lucid-MS, Quantum BioPharma’s investigational compound aimed at inhibiting demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation.

“A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination,” said a recent article. “Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.”

Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models.

In addition to its MS research, Quantum BioPharma has developed unbuzzd, a product designed to address alcohol misuse, and has spun out its OTC version to Unbuzzd Wellness Inc. (UWI). Quantum BioPharma retains a 19.84% ownership stake in UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity.

The company continues to focus on its core mission of addressing challenging diseases, and the progress in the MS imaging study represents a step forward in validating the potential of Lucid-MS. For more information on Quantum BioPharma and its pipeline, visit the company’s newsroom at https://ibn.fm/QNTM.